Poorly Soluble Drugs
portes grátis
Poorly Soluble Drugs
Dissolution and Drug Release
Bell, Robert G.; Jackson, J. Derek; Webster, Gregory K.
Pan Stanford Publishing Pte Ltd
12/2016
728
Dura
Inglês
9789814745451
15 a 20 dias
1510
Descrição não disponível.
Introduction. Solubility determination for pharmaceutical API. Use of surfactants in dissolution testing. Intrinsic dissolution evaluation of poorly soluble drugs. Oral delivery of poorly soluble drugs. A staged approach to pharmaceutical dissolution testing. Development and application of in vitro two-phase dissolution method for poorly water soluble drugs. The use of Apparatus 3 in dissolution testing of poorly soluble drug formulations. Use of Apparatus 4 in dissolution testing, including sparingly and poorly soluble drugs. Dissolution of nanoparticle drug formulations. Dissolution of lipid based drug formulations. Dissolution of stabilized amorphous drug formulations. Dissolution of pharmaceutical suspensions. Dissolution testing of poorly soluble drugs: 'Biorelevant dissolution'. Clinically relevant dissolution for low solubility immediate release products. The QbD approach to method development and validation for dissolution testing. Regulatory considerations in dissolution and drug release of BCS class II and IV compounds. Dissolution of liquid-filled capsules based formulations. Current and emerging non-compendial methods for dissolution testing.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Dissolution Testing;dissolution;USP Apparatus;testing;Dosage Forms;dosage;PSP Book;form;Dissolution Medium;release;Dissolution Method;media;BCS Class;method;Biorelevant Media;substance;Dissolution Rate;biorelevant;Drug Substance;sink;Non-sink Conditions;Drug Release;Amorphous Solid Dispersion;UV Imaging;Capsule Shell;Solid Dispersion;Dissolution Test Method;Biorelevant Dissolution;Nanoparticle Drug Formulations;SEDDS Formulation;BCS Ii;Vivo Performance;Compacted Drug;Hot Melt Extrusion;Reciprocating Cylinder
Introduction. Solubility determination for pharmaceutical API. Use of surfactants in dissolution testing. Intrinsic dissolution evaluation of poorly soluble drugs. Oral delivery of poorly soluble drugs. A staged approach to pharmaceutical dissolution testing. Development and application of in vitro two-phase dissolution method for poorly water soluble drugs. The use of Apparatus 3 in dissolution testing of poorly soluble drug formulations. Use of Apparatus 4 in dissolution testing, including sparingly and poorly soluble drugs. Dissolution of nanoparticle drug formulations. Dissolution of lipid based drug formulations. Dissolution of stabilized amorphous drug formulations. Dissolution of pharmaceutical suspensions. Dissolution testing of poorly soluble drugs: 'Biorelevant dissolution'. Clinically relevant dissolution for low solubility immediate release products. The QbD approach to method development and validation for dissolution testing. Regulatory considerations in dissolution and drug release of BCS class II and IV compounds. Dissolution of liquid-filled capsules based formulations. Current and emerging non-compendial methods for dissolution testing.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Dissolution Testing;dissolution;USP Apparatus;testing;Dosage Forms;dosage;PSP Book;form;Dissolution Medium;release;Dissolution Method;media;BCS Class;method;Biorelevant Media;substance;Dissolution Rate;biorelevant;Drug Substance;sink;Non-sink Conditions;Drug Release;Amorphous Solid Dispersion;UV Imaging;Capsule Shell;Solid Dispersion;Dissolution Test Method;Biorelevant Dissolution;Nanoparticle Drug Formulations;SEDDS Formulation;BCS Ii;Vivo Performance;Compacted Drug;Hot Melt Extrusion;Reciprocating Cylinder
